Holen Sie sich die Stockscreener-App
116.38
0.61%
-0.71
Vorhandelsmarkt:
116.38
Schlusskurs vom Vortag:
$117.09
Offen:
$117.09
24-Stunden-Volumen:
643.45K
Relative Volume:
0.35
Marktkapitalisierung:
$8.89B
Einnahmen:
$8.10B
Nettoeinkommen (Verlust:
$599.48M
KGV:
15.73
EPS:
7.3969
Netto-Cashflow:
$971.25M
1W Leistung:
-6.51%
1M Leistung:
-0.10%
6M Leistung:
-28.24%
1J Leistung:
-10.93%
1-Tages-Spanne:
$115.28
$118.70
1-Wochen-Bereich:
$115.28
$124.80
52-Wochen-Spanne:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Compare ICLR vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
116.38 | 8.94B | 8.10B | 599.48M | 971.25M | 7.3969 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2026-02-23 | Hochstufung | Jefferies | Hold → Buy |
| 2026-02-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-17 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | Herabstufung | Truist | Buy → Hold |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-09-09 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-03 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
ICON expands US early phase research capabilities with new clinic and outpatient centres - MSN
ICON plc stock (IE0005711209): clinical research specialist after solid Q1 update - AD HOC NEWS
ICLR SEC FilingsICON PLC 10-K, 10-Q, 8-K Forms - Stock Titan
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fra - GuruFocus
Harris Associates L.P. discloses 5.7% stake in ICON plc (ICLR) - Stock Titan
Orbis, Allan Gray file Schedule 13G/A for ICON PLC (ICLR) reporting 0 shares - Stock Titan
Hybrid Clinical Research Job at ICON | Life Science Graduates Must Apply! - BioTecNika
ICON PLC (NASDAQ: ICLR) director logs 5,005-option expiration extension - Stock Titan
ICON PLC (ICLR) director logs mixed transactions on 5,005 stock options - Stock Titan
ICON PLC (ICLR) director reshapes 3,255 stock options in Form 4 - Stock Titan
Wellington entities report 7.74% stake in Icon (ICLR) - Stock Titan
Icon Opens New Clinical Facilities in Move to Expand Early-Phase Capabilities - Moomoo
ICON plc stock (IE0005711209): Expands early-phase research with new Texas clinic - AD HOC NEWS
ICON opens new Texas clinical research unit - BioXconomy
ICON (ICLR) Expands Early Phase Capabilities with New Facilities - GuruFocus
A Look at Icon PLC (ICLR) After 3.7% Decline -- GF Value $241.78 vs Price $117.38 - GuruFocus
Icon announces new Clinical Research Unit in San Antonio, Texas - TipRanks
Icon Expands Early Phase Capabilities - Contract Pharma
ICON's New Texas Hub Aims to Reshape Early Phase Drug Trials - BriefGlance
Hybrid Clinical Research Associate Job at ICON plc | Apply Now - BioTecNika
Templeton Growth Fund, Inc.'s Icon PLC(ICLR) Holding History - GuruFocus
Does ICON (ICLR)ʼs 20‑F Delay Reshape the Narrative Around Its Strong Institutional Ownership Base? - Sahm
A Look at Icon PLC (ICLR) After 4.7% Decline -- GF Value $241.81 vs Price $118.96 - GuruFocus
ICON earnings on deck: Can CRO move past accounting cloud? - Investing.com UK
ICON plc Delays Annual 20-F Amid Restatement - TipRanks
Invesco Ltd. takes 5.1% stake in ICON PLC (ICLR) via 3.88M shares - Stock Titan
FMR LLC discloses 4,174,005.50 shares in ICON PLC (ICLR) on Schedule 13G - Stock Titan
HealthVerity to acquire data platform Symphony Health - MobiHealthNews
Principal Financial Group Inc. Cuts Stock Position in Icon Plc $ICLR - MarketBeat
MSN Money - msn.com
Leerink Partners Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $125 - Moomoo
Icon Plc $ICLR Position Trimmed by Kornitzer Capital Management Inc. KS - MarketBeat
ICON (ICLR) Delays 20-F for Multi-Year Revenue Restatements Is Governance Now the Key Risk? - simplywall.st
Icon PLC | NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F - Moomoo
Is Icon PLC (ICLR) a Bargain After 4.8% Drop? GF Value Says Unde - GuruFocus
Truist Financial Maintains Icon PLC(ICLR.US) With Hold Rating, Announces Target Price $139 - 富途牛牛
ICLR Price Today: Icon Plc Stock Price, Quote & Chart | MEXC - MEXC Exchange
William Blair Maintains Icon PLC(ICLR.US) With Buy Rating - Moomoo
What Just Happened at ICON (ICLR) and Why Did Shares Soar - Kavout
Jennison Associates LLC Makes New $123.54 Million Investment in Icon Plc $ICLR - MarketBeat
Truist reiterates Hold rating on ICON stock, $139 price target - Investing.com UK
Truist reiterates Hold rating on ICON stock, $139 price target By Investing.com - Investing.com India
ICON to Restate 2023–2025 Results After Audit Flags Revenue Recognition Issues - The Globe and Mail
Is It Too Late to Buy Icon PLC (ICLR) After 13.3% Rally? GF Value Says Undervalued - GuruFocus
Icon Clears the Air: Accounting Adjustments Prove Less Severe Than Feared - AD HOC NEWS
ICLR Stock Holds Support As Traders Watch Next Move - StocksToTrade
ICLR Stock Climbs As Support Holds And Value Case Builds - timothysykes.com
ICON Public Limited (ICLR) Shares Surge 13% Following Investigat - GuruFocus
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):